Innovative Alzheimer Therapy Shows Promise in Recent Study
Anavex Life Sciences has announced encouraging results from a recent phase 2b/3 trial of its investigational
therapy, blarcamesine (ANAVEX2-73), aimed at treating early Alzheimer disease.
The study, conducted across multiple countries, involved 508 participants and
demonstrated a significant reduction in pathological amyloid-ß levels, a
hallmark of Alzheimer's pathology.
The trial, which included randomized, double-blind,...